Teva Infringed License, Must Return Proneuron’s IP Rights, Israeli Court Rules

Proneuron Biotechnologies won a longstanding intellectual property suit against Teva Pharmaceuticals on April 27, when the Tel Aviv District Court ruled that Teva had infringed the terms of a license it received from Proneuron, and must return Proneuron’s technology and intellectual property rights immediately.

Proneuron filed suit against Teva in 2007, claiming that the world’s largest generic drug maker signed a development agreement with it, and then launched a “doomed” clinical trial of Proneuron’s technology, simply in order to tie-up that technology and protect Teva’s other commercial interests, including its proprietary desire keep to itself the molecule on which its ...